Education
About Us
Working with TipRanks
Follow Us
CombiGene AB (SE:LARK)
:LARK
Top Page
CombiGene AB
(LARK)
Select Model
Select Model
Rating:52Neutral
Price Target:―
CombiGene AB's overall stock score reflects substantial financial challenges, with declining revenues and negative cash flows being key risks. The technical analysis indicates a neutral trend, but the valuation remains unattractive due to ongoing losses. The lack of earnings call data and corporate events does not provide additional clarity or optimism for the stock's immediate outlook.
CombiGene AB (LARK) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
€50.30M
Dividend Yield8.1%
Average Volume (3M)41.41K
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue Growth-94.12%
EPS Growth-25.83%
CountrySE
Employees9
SectorFinancial
Sector Strength70
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.62
Shares Outstanding19,801,197
10 Day Avg. Volume70,026
30 Day Avg. Volume41,406
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CombiGene AB Business Overview & Revenue Model
Company DescriptionCombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.
How the Company Makes MoneyCombiGene makes money primarily through the development and commercialization of its gene therapy products. The company generates revenue by partnering with larger pharmaceutical companies for the co-development, licensing, and distribution of its therapies. These partnerships often include upfront payments, milestone payments, and royalties on sales. Additionally, CombiGene may secure funding from grants and research collaborations with academic institutions and research organizations, which support the advancement of its therapeutic programs.
CombiGene AB Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
68
Positive
Cash Flow
35
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
CombiGene AB Technical Analysis
Positive
2.54
Price Trends
2.42
Positive
2.39
Positive
2.31
Positive
Market Momentum
0.04
Negative
53.69
Neutral
45.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LARK, the sentiment is Positive. The current price of 2.54 is above the 20-day moving average (MA) of 2.40, above the 50-day MA of 2.42, and above the 200-day MA of 2.31, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 53.69 is Neutral, neither overbought nor oversold. The STOCH value of 45.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:LARK.
CombiGene AB Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
52 Neutral | €50.30M | ― | ― | 8.10% | -94.12% | -25.83% | |
41 Neutral | kr57.15M | ― | -97.11% | ― | -13.08% | 32.78% | |
39 Underperform | kr73.86M | ― | -136.44% | ― | -30.49% | -242.26% | |
37 Underperform | €8.13M | ― | -112.33% | ― | ― | 88.59% | |
34 Underperform | kr15.22M | ― | -83.38% | ― | ― | 68.74% |
* Financial Sector Average
SE:LARK
CombiGene AB
2.54
0.35
16.03%
SE:2CUREX
2cureX AB
1.54
1.00
182.57%
SE:STABL
Stayble Therapeutics AB
0.24
-0.38
-61.94%
SE:LIDDS
LIDDS AB
0.06
-0.05
-47.32%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
21.50
-13.78
-39.06%
SE:SPRINT
Sprint Bioscience AB
0.70
-1.03
-59.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.